US2013259841A1PendingUtilityA1

Mesenchymal Stem Cells Expressing TNF-alpha Receptors

60
Assignee: OSIRIS THERAPEUTICS INCPriority: Jan 13, 2006Filed: May 31, 2013Published: Oct 3, 2013
Est. expiryJan 13, 2026(expired)· nominal 20-yr term from priority
Inventors:Alla DanilkovitchDiane CarterAlicia TyrellSimon BubnicMichelle MarcelinoRodney Monroy
A61P 35/00A61P 29/00G01N 2333/525C12N 2501/25A61K 35/28C12N 5/0663A61K 2035/122C12N 5/0662
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 6 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.

Claims

exact text as granted — not AI-modified
1 . A composition comprising mesenchymal stem cells wherein said mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 13 pg/10 6  cells. 
     
     
         2 . The composition of  claim 1  wherein said mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 15 pg/10 6  cells. 
     
     
         3 . The composition of  claim 2  wherein said mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 18 pg/10 6  cells. 
     
     
         4 . The composition of  claim 1  wherein said mesenchymal stem cells are human mesenchymal stem cells. 
     
     
         5 . The composition of  claim 1 , and further comprising an acceptable pharmaceutical carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.